Tesla Raises Cybertruck Prices by $5,000 in US 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Nvidia Options Price in $280 Billion Earnings Swing 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
Trump Buys SpaceX Shares After Record IPO 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Anthropic IPO Could Challenge SpaceX’s Record $86 Billion Offering 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Add as a preferred source on Google
SAN CARLOS, Calif., May 03, 2018 -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its first quarter 2018 financial and operating results on Thursday, May 10, 2018. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.
In order to participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 2995797. The live webcast can be accessed under “News & Events” in the “Investors” section of the Company’s website at http://www.iovance.com/ or you may use the link: https://edge.media-server.com/m6/p/ouykqu6a.
A replay of the call will be available from May 10, 2018 at 7:30 p.m. ET to May 17, 2018 at 8:30 p.m. ET. To access the replay, please dial 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and reference the access code 2995797. The archived webcast will be available for thirty days in the Investors section of Iovance Biotherapeutics’ website at http://www.iovance.com/.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck, recurrent, metastatic or persistent cervical cancer, and locally advanced or metastatic non-small cell lung cancer. For more information, please visit http://www.iovance.com.
Investor Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Media Contact:
Evan Smith
FTI Consulting
212-850-5622
[email protected]
